In this study, we report the association of the rs738407, rs738409, and rs2896019 variants of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) (adiponutrin) gene with nonalcoholic steatohepatitis (NASH) (χ2=14.528, p=0.001; χ2=18.882, p=0.000; χ2=7.449, p=0.024, respectively) in 80 patients with NASH and 303 healthy controls. We genotyped the subjects using three polymerase chain reaction-restriction fragment length polymorphism methods developed in our laboratory. Our findings confirm the findings of the recent case-control and genome-wide association studies carried out in different populations around the world. Thus, the three variants in PNPLA3 gene may be a genetic risk factor for NASH.
Get full access to this article
View all access options for this article.
References
1.
BasantaniMK, SitnickMT, CaiL, et al. (2011) Pnpla3/adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res, 52:318-329.
2.
BaulandeS, LasnierF, LucasM, PairaultJ (2001) Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem, 276:33336-33344.
3.
BruntEM, JanneyCG, Di BisceglieAM, et al. (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 94:2467-2474.
4.
ChalasaniN, GuoX, LoombaR, et al. (2010) Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology, 139:1567-1576.
5.
ChenW, ChangB, LiL, ChanL (2010) Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology, 52:1134-1142.
6.
DentinR, BenhamedF, HainaultI, et al. (2006) Liver specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes, 55:2159-2170.
7.
DesgrosellierJS, ChereshDA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 10:9-22.
8.
DonnellyKL, SmithCI, SchwarzenbergSJ, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patientswith nonalcoholic fatty liver disease. J Clin Invest, 115:1343-1351.
GuyotE, SuttonA, RufatP, et al. (2013) PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol, 58:312-318.
HottaK, YonedaM, HyogoH, et al. (2010) Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet, 11:172-182.
14.
IshiiS, IizukaK, MillerBC, UyedaK (2004) Carbohydrate response element bindingprotein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A, 101:15597-15602.
15.
JenkinsCM, MancusoDJ, YanW, et al. (2004) Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem, 279:48968-48975.
16.
KawaguchiT, SumidaY, UmemuraA, et al. (2012) Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One, 7:e38322
17.
KimuraM, MurakamiT, Kizaka-KondohS, et al. (2010) Functional molecular imaging of ILK-mediated Akt/PKB signaling cascades and the associated role of beta-parvin. J Cell Sci, 123:747-755.
18.
KitamotoT, KitamotoA, YonedaM, et al. (2013) Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet, 132:783-792.
19.
KleinerDE, BruntEM (2012) Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis, 32:3-13.
20.
KotronenA, JohanssonLE, JohanssonLM, et al. (2009) A common variant in PNPLA3, which encodes adiponutrin, isassociated with liver fat content in humans. Diabetologia, 52:1056-1060.
21.
LakeAC, SunY, LiJL, et al. (2005) Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res, 46:2477-2487.
22.
Larrieta-CarrascoE, León-MimilaP, Villarreal-MolinaT, et al. (2013) Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Gene, 520:185-188.
23.
LiJZ, HuangY, KaramanR, et al. (2012) Chronic overexpression of PNPLA3I148 M in mouse liver causes hepatic steatosis. J Clin Invest, 122:4130-4144.
24.
LudwigJ, ViggianoTR, McGillDB, OhBJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 55:434-438.
25.
MaL, TsatsosNG, TowleHC (2005) Direct role of ChREBP Mlx in regulating hepaticglucose-responsive genes. J Biol Chem, 280:12019-12027.
26.
MatteoniCA, YounossiZM, GramlichT, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 116:1413-1419.
27.
MillerSA, DykesDD, PoleskyHF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16:1215.
28.
PatsenkerE, StickelF (2011) Role of integrins in fibrosing liver diseases. Am J Physiol Gastrointest Liver Physiol, 301:G425-G434.
29.
PengXE, WuYL, LinSW, et al. (2012) Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One, 7:e50256.
30.
PosticC, DentinR, DenechaudPD, GirardJ (2007) ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr, 27:179-192.
31.
PosticC, GirardJ (2008) Contribution of de novo fatty acid synthesis to hepaticsteatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest, 118:829-838.
32.
RomeoS, KozlitinaJ, XingC, et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet, 40:1461-1465.
33.
RomeoS, SentinelliF, CambuliVM, et al. (2010) The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol, 53:335-338.
34.
RotmanY, KohC, ZmudaJM, et al. (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 52:894-903.
35.
SazciA, AkpinarG, AygunC, et al. (2008a) Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig Dis Sci, 53:3218-3224.
36.
SazciA, ErgulE, AygunC, et al. (2008b) Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochem Funct, 26:291-296.
37.
SazciA, OzelMD, ErgulE, AygunC (2013) Association of nicotinamide-N-methyltransferase gene rs694539 variant with patients with nonalcoholic steatohepatitis. Genet Test Mol Biomarkers, 17:849-853.
38.
ShimomuraI, BashmakovY, HortonJD (1999) Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem, 274:30028-30032.
39.
SpeliotesEK, ButlerJL, PalmerCD, et al. (2010) PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology, 52:904-912.
40.
SpeliotesEK, Yerges-ArmstrongLM, WuJ, et al. (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet, 7:e1001324
41.
SookoianS, PirolaCJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology, 53:1883-1894.
42.
StoeckmanAK, MaL, TowleHC (2004) Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes. J Biol Chem, 279:15662-15669.
43.
TianC, StokowskiRP, KershenobichD, et al. (2010) Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet, 42:21-23.
44.
ValentiL, AlisiA, GalmozziE, et al. (2010) I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology, 52:1274-1280.
45.
ValentiL, NobiliV, Al-SerriA, et al. (2011) The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol, 55:1409-1414.
46.
Wilfred de AlwisNM, DayCP (2008) Genes and nonalcoholic fattyliver disease. Curr Diab Rep, 8:156-163.
47.
WilsonPA, GardnerSD, LambieNM, et al. (2006) Characterization of the human patatin-like phospholipase family. J Lipid Res, 47:1940-1948.
48.
YahagiN, ShimanoH, HastyAH, et al. (2002) Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem, 77:19353-19357.
49.
ZainSM, MohamedR, MahadevaS, et al. (2012) A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet, 131:1145-1152.
